Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | EVP | March 04, 2022 | March 09, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sarepta Therapeutics, Inc.
Report date March 04, 2022 · Filed March 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,099 |
Reported balance
After 2022-03-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-03-04 · Tax withholding · Disposed 1,160 · Balance 14,099 F1: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021. F2: The amount of securities directly owned by the reporting person includes the following shares of common stock purchased under the Company's Amended and Restated 2013 Employee Stock Purchase Plan: 77 shares on February 28, 2022, 75 shares on August 31, 2021, 62 shares on February 28, 2021 and 45 shares on August 31, 2020. |
| Common StockSEC Table I · non-derivative | Direct | 22,099 |
Reported balance
After 2022-03-07 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-03-07 · Grant · Acquired 8,000 · Balance 22,099 F3: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $80.42 · Expires 2032-03-07 | Direct | 48,000 |
Reported balance
After 2022-03-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-07 · Grant · Acquired 48,000 · Balance 48,000 F4: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021.
F2: The amount of securities directly owned by the reporting person includes the following shares of common stock purchased under the Company's Amended and Restated 2013 Employee Stock Purchase Plan: 77 shares on February 28, 2022, 75 shares on August 31, 2021, 62 shares on February 28, 2021 and 45 shares on August 31, 2020.
F3: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date.
F4: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 07, 2022 Filed Mar 9, 2022 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 48,000 | $0.00 Strike: $80.42 | $0.00 |
DisclosureSEC source: 0001209191-22-017345 · doc4.xml · derivative · entry 3 Ciambrone William · CIK 0001794135 · EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2032-03-07 F4 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017345 · doc4.xml · nonDerivative · entry 2 Ciambrone William · CIK 0001794135 · EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,099 F3 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 1,160 | $79.20 | $91,872.00 |
DisclosureSEC source: 0001209191-22-017345 · doc4.xml · nonDerivative · entry 1 Ciambrone William · CIK 0001794135 · EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,099 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021. F2 · balance_after: The amount of securities directly owned by the reporting person includes the following shares of common stock purchased under the Company's Amended and Restated 2013 Employee Stock Purchase Plan: 77 shares on February 28, 2022, 75 shares on August 31, 2021, 62 shares on February 28, 2021 and 45 shares on August 31, 2020. Read SEC document |
| March 03, 2021 Filed Mar 6, 2021 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $87.11 | $0.00 |
DisclosureSEC source: 0001209191-21-018415 · doc4.xml · derivative · entry 2 Ciambrone William · CIK 0001794135 · EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-03-03 F2 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. Read SEC document |
| March 03, 2021 Filed Mar 6, 2021 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018415 · doc4.xml · nonDerivative · entry 1 Ciambrone William · CIK 0001794135 · EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date. Read SEC document |
| November 18, 2019 Filed Nov 21, 2019 01:34 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 80,000 | $0.00 Strike: $97.90 | $0.00 |
DisclosureSEC source: 0001209191-19-057542 · doc4.xml · derivative · entry 1 Ciambrone William · CIK 0001794135 · EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2029-11-18 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant, in each case, subject to Mr. Ciambrone's continued employment with the Issuer on such vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.